Company
InnoCare Pharma
InnoCare Pharma has 23 drugs tracked on RxWires: 7 in Phase 3, 4 in Phase 2, 4 in Phase 1/2, 7 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| ICP-488 Tablets | Phase 3 | Plaque Psoriasis Patients |
| ICP-022 | Phase 3 | Chronic Lymphocytic Leukemia |
| Tafasitamab | Phase 3 | DLBCL |
| Orelabrutinib | Phase 3 | Chronic Primary Immune Thrombocytopenia (ITP) |
| ICP-248 | Phase 3 | Relapsed or Refractory Mantle Cell Lymphoma (MCL) |
| Orelabrutinib + R-CHOP | Phase 3 | Diffuse Large B Cell Lymphoma (DLBCL) |
| ICP-332 Tablets | Phase 3 | Atopic Dermatitis |
| ICP-192 | Phase 2 | Bladder Urothelial Cancer |
| Tafasitamab and Lenalidomide | Phase 2 | DLBCL |
| ICP-322 | Phase 2 | Prurigo Nodularis (PN) |
| Orelabrutinib High dose | Phase 2 | Mantle Cell Lymphoma |
| ICP-490 | Phase 1/2 | Relapsed or Refractory Non-Hodgkin Lymphoma |
| ICP-B381 | Phase 1/2 | Advanced Solid Tumor |
| Drug ICP-192 | Phase 1/2 | Advanced Solid Tumors |
| ICP-723 | Phase 1/2 | Solid Tumors |
| ICP-189 | Phase 1 | Patients With Advanced Solid Tumors |
| ICP-105 | Phase 1 | Solid Tumor |
| Orelabrutinib + Rifampin | Phase 1 | Healthy Person |
| ICP-B794 | Phase 1 | Advanced Solid Tumors |
| ICP-033 tablet | Phase 1 | Patients With Advanced Solid Tumors |
| Orelabrutinib and placebo (orelabrutinib tablet simulator) | Phase 1 | Healthy Subject |
| ICP-538 Tablets | Phase 1 | Health Services Research |
| [14C]ICP-022 | Not Applicable | Healthy Volunteers |
Latest
No recent events.
Follow InnoCare Pharma on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.